Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
UBS
Accenture
Cerilliant
Farmers Insurance
Federal Trade Commission
Baxter
Fish and Richardson
Queensland Health
Chubb

Generated: January 18, 2018

DrugPatentWatch Database Preview

Lilly Company Profile

« Back to Dashboard

Summary for Lilly
International Patents:637
US Patents:26
Tradenames:119
Ingredients:102
NDAs:130

Drugs and US Patents for Lilly

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly KEFLIN IN PLASTIC CONTAINER cephalothin sodium INJECTABLE;INJECTION 062549-002 Sep 10, 1985 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly DROLBAN dromostanolone propionate INJECTABLE;INJECTION 012936-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly HUMULIN 50/50 insulin recombinant human; insulin susp isophane recombinant human INJECTABLE;INJECTION 020100-001 Apr 29, 1992 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA ZYDIS olanzapine TABLET, ORALLY DISINTEGRATING;ORAL 021086-003 Apr 6, 2000 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly NPH ILETIN I (BEEF-PORK) insulin susp isophane beef/pork INJECTABLE;INJECTION 017936-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly CIALIS tadalafil TABLET;ORAL 021368-001 Nov 21, 2003 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly TAZIDIME IN PLASTIC CONTAINER ceftazidime INJECTABLE;INJECTION 062739-002 Jul 10, 1986 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly HUMULIN 70/30 PEN insulin recombinant human; insulin susp isophane recombinant human INJECTABLE;INJECTION 019717-002 Aug 6, 1998 OTC Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-005 Nov 26, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-001 Nov 26, 2002 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Lilly

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly ZYPREXA ZYDIS olanzapine TABLET, ORALLY DISINTEGRATING;ORAL 021086-002 Apr 6, 2000 ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA ZYDIS olanzapine TABLET, ORALLY DISINTEGRATING;ORAL 021086-004 Apr 6, 2000 ➤ Subscribe ➤ Subscribe
Lilly ALIMTA pemetrexed disodium INJECTABLE;IV (INFUSION) 021462-002 Sep 7, 2007 ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-001 Sep 30, 1996 ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA ZYDIS olanzapine TABLET, ORALLY DISINTEGRATING;ORAL 021086-001 Apr 6, 2000 ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-002 Sep 30, 1996 ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA ZYDIS olanzapine TABLET, ORALLY DISINTEGRATING;ORAL 021086-004 Apr 6, 2000 ➤ Subscribe ➤ Subscribe
Lilly CIALIS tadalafil TABLET;ORAL 021368-001 Nov 21, 2003 ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-002 Sep 30, 1996 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for LILLY drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe For Injection 750 mg/vial ➤ Subscribe 10/6/2016
➤ Subscribe Injection 250 mcg/mL, 2.4 mL prefilled Pen ➤ Subscribe 7/27/2015
➤ Subscribe For Injection 1000 mg/vial ➤ Subscribe 6/27/2012
➤ Subscribe Delayed-release Capsules 40 mg ➤ Subscribe 5/10/2012
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 10/14/2008
➤ Subscribe Delayed-release Capsules 20 mg, 30 mg and 60 mg ➤ Subscribe 8/4/2008
➤ Subscribe For Injection 100 mg/vial ➤ Subscribe 7/1/2008
➤ Subscribe Capsules 3 mg/25 mg ➤ Subscribe 5/8/2008
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe 2/4/2008
➤ Subscribe Tablets 5 mg, 10 mg and 20 mg ➤ Subscribe 11/21/2007
➤ Subscribe For Injection 2 g/vial ➤ Subscribe 8/24/2007
➤ Subscribe Capsules 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg ➤ Subscribe 5/29/2007
➤ Subscribe For Injection 1g/vial ➤ Subscribe 11/14/2005
➤ Subscribe For Injection 200 mg/vial ➤ Subscribe 11/1/2005
➤ Subscribe Capsules 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg ➤ Subscribe 1/10/2005
Premature patent expirations for LILLY

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Subscribe ➤ Subscribe
➤ Subscribe ➤ Subscribe
➤ Subscribe ➤ Subscribe

Non-Orange Book US Patents for Lilly

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,025,494 Tetracyclic derivatives, process of preparation and use ➤ Subscribe
6,841,167 .beta.-carboline pharmaceutical compositions ➤ Subscribe
4,996,206 N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives ➤ Subscribe
7,427,275 Medication dispensing apparatus with triple screw threads for mechanical advantage ➤ Subscribe
6,369,059 Tetracyclic derivatives, process of preparation and use ➤ Subscribe
5,028,608 N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives ➤ Subscribe
6,127,542 Tetracyclic derivatives, process of preparation and use ➤ Subscribe
5,981,527 Cyclic GMP-specific phosphodiesterase inhibitors ➤ Subscribe
5,248,775 Pyrrolo(2,3-d)pyrimidines ➤ Subscribe
7,857,791 Medication dispensing apparatus with gear set having drive member accommodating opening ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Lilly Drugs

Supplementary Protection Certificates for Lilly Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
678 Luxembourg ➤ Subscribe PRODUCT NAME: TOBRAMYCINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE. FIRST REGISTRATION: 20110725
0124 Netherlands ➤ Subscribe 300124, 20150119, EXPIRES: 20171111
2004005,C0792290 Lithuania ➤ Subscribe PRODUCT NAME: INSULIN DETEMIR; REGISTRATION NO/DATE: EU/1/04/278/001, EU/1/04/278/002, EU/1/04/278/003, EU/1/04/278/004, EU/1/04/278/005, EU/1/04/278/006, EU/1/04/278/007, EU/1/04/278/008, EU/1/04/278/00 20040601
/2004 Austria ➤ Subscribe PRODUCT NAME: INSULIN-DETEMIR UND PHARMAZEUTISCH ANNEHMBARE ZN-SALZE DAVON; NAT. REGISTRATION NO/DATE: EU/1/04/278/001-009 20040601; FIRST REGISTRATION: LI 56370 56371 56372 20031110
2107069/02 Switzerland ➤ Subscribe PRODUCT NAME: INSULIN DEGLUDEC + INSULIN ASPART; REGISTRATION NO/DATE: SWISSMEDIC 62648 12.09.2013
00021 Netherlands ➤ Subscribe PRODUCT NAME: INSULINE ASPART EN GEKRISTALLISEERD PROTAMINE-INSULINE ASPART; NAT. REGISTRATION NO/DATE: EU/1/00/142/001 20000801; FIRST REGISTRATION: 55414015541502 2000230623
/2015 Austria ➤ Subscribe PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720
C/GB00/027 United Kingdom ➤ Subscribe PRODUCT NAME: INSULIN ASPART AND PROTAMINE (NOVOMIX 30); REGISTERED: CH 55414 01 20000623; CH 55415 02 20000623; CH 55416 02 20000623; UK EU/1/00/142/001-008 20000801
C/GB05/003 United Kingdom ➤ Subscribe PRODUCT NAME: DULOXETINE AND PHARMACUETICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, AND IN PARTICULAR DULOXETINE HYDROCHLORIDE; REGISTERED: UK EU/1/04/280/001 20040811; UK EU/1/04/280/002 20040811; UK EU/1/04/280/003 20040811; UK EU/1/04/280/004 20040811; UK EU/1/04/280/005 20040811; UK EU/1/04/280/006 20040811
/2005 Austria ➤ Subscribe PRODUCT NAME: NOVOMIX 70 - SUSPENSION, ENTHALTEND LOESLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHAELTNIS 70:30; REGISTRATION NO/DATE: EU/1/00/142/017 - EU/1/00/142/022 20051005
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Fish and Richardson
Chinese Patent Office
QuintilesIMS
Daiichi Sankyo
Colorcon
Mallinckrodt
Fuji
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot